Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
92.57
+1.48 (1.62%)
At close: Dec 20, 2024, 4:00 PM
92.15
-0.42 (-0.45%)
After-hours: Dec 20, 2024, 6:57 PM EST
Gilead Sciences Employees
Gilead Sciences had 18,000 employees as of December 31, 2023. The number of employees increased by 1,000 or 5.88% compared to the previous year.
Employees
18,000
Change (1Y)
1,000
Growth (1Y)
5.88%
Revenue / Employee
$1,572,167
Profits / Employee
$7,000
Market Cap
115.37B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 18,000 | 1,000 | 5.88% |
Dec 31, 2022 | 17,000 | 2,600 | 18.06% |
Dec 31, 2021 | 14,400 | 800 | 5.88% |
Dec 31, 2020 | 13,600 | 2,600 | 23.64% |
Jan 31, 2019 | 11,000 | 1,000 | 10.00% |
Jan 31, 2018 | 10,000 | 1,000 | 11.11% |
Jan 31, 2017 | 9,000 | 1,000 | 12.50% |
Jan 31, 2016 | 8,000 | 1,000 | 14.29% |
Jan 31, 2015 | 7,000 | 900 | 14.75% |
Jan 31, 2014 | 6,100 | 1,100 | 22.00% |
Jan 31, 2013 | 5,000 | 500 | 11.11% |
Jan 31, 2012 | 4,500 | 500 | 12.50% |
Jan 31, 2011 | 4,000 | 148 | 3.84% |
Jan 31, 2010 | 3,852 | 411 | 11.94% |
Jan 31, 2009 | 3,441 | 462 | 15.51% |
Jan 31, 2008 | 2,979 | 464 | 18.45% |
Jan 31, 2007 | 2,515 | 615 | 32.37% |
Jan 31, 2006 | 1,900 | 246 | 14.87% |
Feb 28, 2005 | 1,654 | 229 | 16.07% |
Feb 27, 2004 | 1,425 | 175 | 14.00% |
Feb 28, 2003 | 1,250 | 250 | 25.00% |
Feb 28, 2002 | 1,000 | 150 | 17.65% |
Feb 28, 2001 | 850 | 90 | 11.84% |
Dec 31, 1999 | 760 | 467 | 159.39% |
Dec 31, 1998 | 293 | 4 | 1.38% |
Dec 31, 1997 | 289 | 41 | 16.53% |
Dec 31, 1996 | 248 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Elevance Health | 104,900 |
Medtronic | 95,000 |
Sanofi | 86,088 |
The Cigna Group | 72,500 |
Boston Scientific | 48,000 |
Bristol-Myers Squibb Company | 34,100 |
Amgen | 26,700 |
Stryker | 26,700 |
GILD News
- 1 day ago - Gilead Sciences to Present at Upcoming Investor Conference - Business Wire
- 3 days ago - Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure - Seeking Alpha
- 4 days ago - U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer - Business Wire
- 4 days ago - Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies - Business Wire
- 8 days ago - Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis - Business Wire
- 9 days ago - Gilead appoints Sanofi official Dietmar Berger as next chief medical officer - Reuters
- 9 days ago - Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer - Business Wire
- 12 days ago - Kite's Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024 - Business Wire